Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company’s lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenn... Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company’s lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.001 | -25 | 0.004 | 0.005 | 0.003 | 7549229 | 0.00392346 | DE |
| 4 | -0.002 | -40 | 0.005 | 0.005 | 0.003 | 3229923 | 0.00407142 | DE |
| 12 | -0.003 | -50 | 0.006 | 0.006 | 0.003 | 3269183 | 0.00451214 | DE |
| 26 | -0.006 | -66.6666666667 | 0.009 | 0.01 | 0.003 | 2010436 | 0.00510386 | DE |
| 52 | -0.006 | -66.6666666667 | 0.009 | 0.013 | 0.003 | 1867394 | 0.00715749 | DE |
| 156 | -0.055 | -94.8275862069 | 0.058 | 0.14 | 0.003 | 3145384 | 0.0216227 | DE |
| 260 | -0.055 | -94.8275862069 | 0.058 | 0.14 | 0.003 | 3145384 | 0.0216227 | DE |
eagle8
2分前
Implanting
3分前
Methinks
3分前
tkg
4分前
Methinks
5分前
Iwasbornpoor
17分前
eagle8
26分前
sctts
30分前
price_and_volume
48分前
Iwasbornpoor
53分前
price_and_volume
54分前
chicks0123
57分前
tkg
58分前
Iwasbornpoor
59分前
price_and_volume
1時間前
tkg
1時間前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。